Otsuka America Pharmaceutical, Inc. announced that it is “Great Place to Work-Certified.”
Using validated employee feedback gathered with Great Place to Work’s rigorous, data-driven “For All” methodology, certification confirms at least 7 out of 10 employees have a consistently positive experience at Otsuka, according to information provided by the company.
“We are delighted that Otsuka has been certified as a Great Place to Work,” Angela Colon-Mahoney, vice president, People and Business Services, Otsuka America Pharmaceutical, Inc., said in the statement. “Our unique culture and committed employees make the company truly special. A full 91% of our employees said Otsuka is a great place to work, ranking us among the top companies. I am proud of us, of Otsuka, and to be part of a place where we truly defy limitation so others can too.”
“We congratulate Otsuka America Pharmaceutical, Inc. on its Certification,” Sarah Lewis-Kulin, vice president, Best Workplace List Research, Great Place to Work, said in the statement. “Organizations that earn their employees’ trust create great workplace cultures that deliver outstanding business results.”
Great Place to Work is the global authority on workplace culture. Since 1992, they have surveyed more than 100 million employees around the world and used those deep insights to define what makes a great workplace: trust. Great Place to Work helps organizations quantify their culture and produce better business results by creating a high-trust work experience for all employees.
Emprising, their culture management platform, empowers leaders with the surveys, real-time reporting, and insights they need to make data-driven people decisions. Their unparalleled benchmark data is used to recognize Great Place to Work-Certified companies and the Best Workplaces in the US and more than 60 countries, including the 100 Best Companies to Work For and World’s Best list published annually in “Fortune”.
To learn more, visit greatplacetowork.com, listen to the podcast Better by Great Place to Work, and read “A Great Place to Work for All.”
Otsuka Pharmaceutical Co., Ltd., located in Princeton, researches, develops, manufactures and markets innovative products, with a focus on pharmaceutical products to meet unmet medical needs and nutraceutical products for the maintenance of everyday health.
In pharmaceuticals, Otsuka is a leader in the areas of mental, renal and cardiovascular health and has additional research programs in oncology and on several under-addressed diseases including tuberculosis, a significant global public health issue.
Otsuka established a presence in the U.S. in 1973 and today its U.S. affiliates include Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) and Otsuka America Pharmaceutical, Inc. (OAPI). These two companies’ 1,700 employees in the U.S. develop and commercialize medicines in the areas of mental health, nephrology and cardiology, using cutting-edge technology to address unmet healthcare needs. Otsuka’s most recently approved product in the U.S. is the first-ever treatment for autosomal dominant polycystic kidney disease, a genetic disorder in which fluid-filled cysts develop in the kidneys over time, often leading to kidney failure.
OPDC and OAPI are indirect subsidiaries of Otsuka Pharmaceutical Company, Ltd., which is a subsidiary of Otsuka Holdings Co., Ltd. headquartered in Tokyo, Japan. The Otsuka group of companies employed 47,000 people worldwide and had consolidated sales of approximately USD 13 billion in 2019.
Learn more about Otsuka in the U.S. at www.otsuka-us.com and connect on LinkedIn and Twitter at @OtsukaUS. Otsuka Pharmaceutical Co., Ltd.’s global website is accessible at www.otsuka.co.jp/en/.
